7:05 am Cyclacel Pharma presents non-clinical data providing rationale for Sapacitabine combination treatment with Bcr-Abl inhibitors in CML; over 800 patients have received sapacitabine in clinical studies in patients
View todays social media effects on CYCC
View the latest stocks trending across Twitter. Click to view dashboard
See who Cyclacel is hiring next, click here to view
